Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced today that its Annual General Meeting (AGM) 2026, held in Milan, resulted in shareholder approval of all ordinary agenda motions, including the election of George Garibaldi and Paolo Zocchi as new independent, non-executive board members. However, the extraordinary part of the meeting could not proceed as the required quorum was not reached, leaving those motions unvoted.
Chris Martin, Chairman of the Board of Directors, expressed gratitude to shareholders for their trust and welcomed the newly elected members. He also acknowledged the contributions of Patrick Langlois and Luca Benatti, who stepped down after long-standing service. The failed extraordinary motions could impact strategic decisions, as such votes often involve significant corporate actions like capital increases or structural changes. The lack of quorum may indicate shareholder disengagement or concerns about the proposals.
Newron, a biopharmaceutical company focused on central and peripheral nervous system diseases, is advancing its lead compound evenamide, a first-in-class glutamate modulator for treatment-resistant schizophrenia (TRS). The drug is currently in the global pivotal ENIGMA-TRS Phase III program, with promising efficacy and safety data. The company has partnerships with EA Pharma (Japan), Myung In Pharm (South Korea), and others for evenamide, while its marketed product Xadago®/safinamide for Parkinson's disease is commercialized by partners in multiple regions. More information is available at www.newron.com.
The failed extraordinary motions could delay potential funding or restructuring plans, but the approved board elections bring new expertise. George Garibaldi and Paolo Zocchi are expected to contribute to governance and strategic oversight. The company's focus remains on executing its clinical programs and commercial partnerships.
